Effects of Hemoglobin-Based Oxygen Carriers on Blood Coagulation

被引：12

作者：

Roghani, Kimia ^{[1
,2
]}

Holtby, Randall J. ^{[1
,3
]}

Jahr, Jonathan S. ^{[1
]}

机构：

[1] UCLA, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Anesthesiol & Perioperat Med, 757 Westwood Plaza,Suite 3325, Los Angeles, CA 90095 USA

[2] Syracuse Univ, Coll Arts & Sci, Dept Biol, Syracuse, NY 13244 USA

[3] St Georges Univ, Sch Med, True Blue Point, Grenada

来源：

JOURNAL OF FUNCTIONAL BIOMATERIALS | 2014年 / 5卷 / 04期

关键词：

HBOC; blood substitute; resuscitation; bleeding; coagulopathy;

D O I：

10.3390/jfb5040288

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

For many decades, Hemoglobin-based oxygen carriers (HBOCs) have been central in the development of resuscitation agents that might provide oxygen delivery in addition to simple volume expansion. Since 80% of the world population lives in areas where fresh blood products are not available, the application of these new solutions may prove to be highly beneficial (Kim and Greenburg 2006). Many improvements have been made to earlier generation HBOCs, but various concerns still remain, including coagulopathy, nitric oxide scavenging, platelet interference and decreased calcium concentration secondary to volume expansion (Jahr et al. 2013). This review will summarize the current challenges faced in developing HBOCs that may be used clinically, in order to guide future research efforts in the field.

引用

页码：288 / 295

页数：8

共 32 条

[21] Hemolink™, an o-raffinose cross-linked haemoglobin-based oxygen carrier, does not affect activation and function of human platelets in whole blood in vitro [J].